WC500185968

More documents

Recommendations

Info

15.1.22. Moroctocog alfa – REFACTO AF (CAP) Evaluation of a PSUSA procedure Regulatory details: PRAC Rapporteur: Doris Stenver (DK) Administrative details: Procedure number(s): EMEA/H/C/000232/PSUSA/02089/201408 MAH(s): Pfizer Limited 15.1.23. Nonacog alfa – BENEFIX (CAP) Evaluation of a PSUSA procedure Regulatory details: PRAC Rapporteur: Brigitte Keller-Stanislawski (DE) Administrative details: Procedure number(s): EMEA/H/C/000139/PSUSA/02183/201408 MAH(s): Pfizer Limited 15.1.24. Pirfenidone – ESBRIET (CAP) Evaluation of a PSUSA procedure Regulatory details: PRAC Rapporteur: Julie Williams (UK) Administrative details: Procedure number(s): EMEA/H/C/002154/PSUSA/02435/201408 MAH(s): InterMune UK Ltd. 15.1.25. Pandemic influenza vaccine (H5N1, whole virion, vero cell derived, inactivated) – PANDEMIC INFLUENZA VACCINE H5N1 BAXTER (CAP) Prepandemic influenza vaccine (H5N1) (whole virion, inactivated, prepared in cell culture) - VEPACEL (CAP) Evaluation of a PSUSA procedure Regulatory details: PRAC Rapporteur: Brigitte Keller-Stanislawski (DE) Administrative details: Procedure number(s): EMEA/H/C/001200/PSUSA/02282/201408, EMEA/H/C/002089/PSUSA/02282/201408 MAH(s): Baxter AG 15.1.26. Protein C – CEPROTIN (CAP), NAP Evaluation of a PSUSA procedure Regulatory details: PRAC Rapporteur: Brigitte Keller-Stanislawski (DE) Administrative details: Procedure number(s): EMEA/H/C/000334/PSUSA/02563/201407 MAH(s): Baxter AG Pharmacovigilance Risk Assessment Committee (PRAC) EMA/PRAC/257790/2015 Page 76/89
15.1.27. Pyronaridine, artesunate – PYRAMAX (Art 58) Evaluation of a PSUSA procedure Regulatory details: PRAC Rapporteur: Arnaud Batz (FR) Administrative details: Procedure number(s): EMEA/H/W/002319/PSUV/0009 Scientific Opinion Holder(s) (SOH): Shin Poong Pharmaceutical Co., Ltd. 15.1.28. Ruxolitinib – JAKAVI (CAP) Evaluation of a PSUSA procedure Regulatory details: PRAC Rapporteur: Ulla Wändel Liminga (SE) Administrative details: Procedure number(s): EMEA/H/C/002464/PSUSA/10015/201408 MAH(s): Novartis Europharm Ltd 15.1.29. Tasonermin – BEROMUN (CAP) Evaluation of a PSUSA procedure Regulatory details: PRAC Rapporteur: Doris Stenver (DK) Administrative details: Procedure number(s): EMEA/H/C/000206/PSUSA/02850/201408 MAH(s): Boehringer Ingelheim International GmbH 15.1.30. Teduglutide – REVESTIVE (CAP) Evaluation of a PSUSA procedure Regulatory details: PRAC Rapporteur: Torbjörn Callreus (DK) Administrative details: Procedure number(s): EMEA/H/C/002345//PSUSA/09305/201408 MAH(s): NPS Pharma Holdings Limited 15.1.31. Teriparatide – FORSTEO (CAP) Evaluation of a PSUSA procedure Regulatory details: PRAC Rapporteur: Julie Williams (UK) Administrative details: Procedure number(s): EMEA/H/C/000425/PSUSA/02903/201409 MAH(s): Eli Lilly Nederland B.V. Pharmacovigilance Risk Assessment Committee (PRAC) EMA/PRAC/257790/2015 Page 77/89
Page 1 and 2:
10 April 2015 EMA/PRAC/257790/2015
Page 3 and 4:
Table of contents 1. Introduction .
Page 5 and 6:
6.2. Follow-up to PSUR procedures .
Page 7 and 8:
12.15. Contacts of the PRAC with ex
Page 9 and 10:
15.1.25. Pandemic influenza vaccine
Page 11 and 12:
1. Introduction 1.1. Welcome and de
Page 13 and 14:
Regulatory details: PRAC Rapporteur
Page 15 and 16:
mainly reported in the published li
Page 17 and 18:
During routine signal detection act
Page 19 and 20:
Taking into account this first repo
Page 21 and 22:
During routine signal detection act
Page 23 and 24:
Summary of recommendation(s) The M
Page 25 and 26: 4.3.5. Sodium containing formulatio
Page 27 and 28: Intended indication(s): Treatment i
Page 29 and 30: Procedure scope: Proposal for a new
Page 31 and 32: association of lenalidomide and sec
Page 33 and 34: 6. Periodic Safety Update Reports (
Page 35 and 36: The next PSUR should be submitted i
Page 37 and 38: 6.1.5. Mecasermin - INCRELEX (CAP)
Page 39 and 40: In the next PSUR, the MAH should pr
Page 41 and 42: The next PSUR should be submitted i
Page 43 and 44: Summary of recommendation(s) and co
Page 45 and 46: 6.1.14. Zoledronic acid - ACLASTA (
Page 47 and 48: Administrative details: Procedure n
Page 49 and 50: Although the PRAC recognised the re
Page 51 and 52: 10.3. Other requests 10.3.1. Antire
Page 53 and 54: 11. Other Safety issues for discuss
Page 55 and 56: 12.2.2. Pharmacovigilance Inspectio
Page 57 and 58: EudraVigilance data analysis system
Page 59 and 60: pharmacovigilance referrals, prepar
Page 61 and 62: account the comments raised. The PR
Page 63 and 64: 14.1.6. Ferric citrate coordination
Page 65 and 66: Procedure scope: Updated RMP (versi
Page 69 and 70: Procedure scope: Extension of indic
Page 71 and 72: Procedure scope: Grouped variation
Page 73 and 74: 15.1.7. Dabrafenib - TAFINLAR (CAP)
Page 75: 15.1.17. Influenza vaccine (split v
Page 79 and 80: 16.1.3. Sodium, magnesium, potassiu
Page 83 and 84: MAH(s): Novartis Europharm Ltd 16.1
Page 85 and 86: 17. ANNEX I - Renewals of the Marke
Page 87 and 88: Name Role Member state or affiliati
Page 89: Name Role Member state or affiliati
show all

WC500185968

Create successful ePaper yourself

Delete template?

Save as template?